Crossfield Fusion

The company's initial strategy centered on a patented technology called the Epicyclotron. By 2021, a working fusion device based on this approach was developed. However, experimental work and detailed modeling revealed that the reactor would not scale as initially projected to achieve a net energy gain. This led to a strategic pivot. Crossfield Fusion is now channeling its technological developments into exploring applications within the hydrogen isotope separation part of the fusion fuel cycle. This new direction aims to support the broader fusion ecosystem, which relies on the economic viability of its fuel cycle.

Financially, the company is privately held and has secured funding through early-stage venture capital and grants. Records show it raised approximately $422K over two seed rounds in April 2020. Institutional investors include Innovate UK, Future Planet Capital, and the UK Innovation Science & Seed Fund.

Crossfield Fusion's long-term vision involves manufacturing compact, factory-producible fusion reactors, roughly the size of small shipping containers, with a potential output of 1MWe of electricity or 2-3MWt of heat. Before reaching this goal, the company sees commercial opportunities for its technology as a high-output, compact neutron source for applications in radiotherapy, medical isotope production, and materials testing. Keywords: nuclear fusion, compact fusion reactor, fusion fuel cycle, hydrogen isotope separation, alternative energy, cleantech, carbon-free energy, Epicyclotron, neutron sources, medical isotopes, radiotherapy, materials testing, James McKenzie, Chris Macdonald-Bradley, UK Innovation Science & Seed Fund, Future Planet Capital